Bottle Label 4 mg (71610 0482 60)
Doxazosin Tablet
Product Images NDC 71610-482
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Doxazosin (NDC 71610-482). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Aphena Pharma Solutions - Tennessee, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Aphena Pharma Solutions (TN)
Chemical Structure (Doxazosin 01)
Not available.*
Table 3 (Doxazosin 02)
The text represents tables of results from clinical studies evaluating the efficacy of doxazosin in treating benign prostatic hyperplasia (BPH). The studies measured changes in maximum flow rate and symptom score of patients before and after taking placebo or doxazosin at various doses. Study 1 involved titration to the maximum dose of 8 mg, while Study 2 involved titration to a fixed dose over 14 weeks. Study 3 involved titration to a fixed dose over 12 weeks. The results show higher mean maximum flow rates and symptom score improvements in patients taking doxazosin compared to placebo, with some statistically significant differences.*
Figure 1 (Doxazosin 03)
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
